Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.G. R. Hudes, C McAleer, M Cornfield et al.|Journal of Clinical Oncology|1997Cited by 273
Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladderRichard E. Greenberg, Peter J. O’Dwyer, Robert R. Bahnson et al.|Urology|1997Cited by 64